Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4151–4200 of 76264
On June 21, 2025, Franklin H. Farris, Jr. attained the age of 75 and, therefore, has retired from CTBI’s Board of Directors.
On June 18, 2025, Claudette J.V. Chan, a member of the Board of Directors and the Secretary of FONAR Corporation (the “Company”), notified the Company of her intention to retire from the Company's Board of Directors, and to retire as Secretary of the Company, effective June 19, 2025.
Gerardo Norcia, DTE Energy Chairman and Chief Executive Officer, was named DTE Energy Executive Chairman effective September 8, 2025 and will remain a full-time employee and director of the Company.
Also on June 18, 2025, David Ruud, Executive Vice President and Chief Financial Officer was named Vice Chairman and Chief Financial Officer, effective September 8, 2025, at which time Mr. Ruud will receive an increase in base salary to $800,000.
Ms. Harris was also elected to the Company’s Board of Directors effective September 8, 2025.
On June 19, 2025, the Board of Directors of DTE Energy Company (the “Company” or “DTE Energy”) elected Joi M. Harris, DTE Energy’s President and Chief Operating Officer, as President and Chief Executive Officer, effective September 8, 2025.
Messrs David Young, a director of the Company since 2015, and John L. Davies, a director of the Company since 2000, have each decided to retire as a director of the Company
Messrs David Young, a director of the Company since 2015, and John L. Davies, a director of the Company since 2000, have each decided to retire as a director of the Company
On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
On June 19, 2025, Mark Smalley, Chief Compliance Officer of Bitcoin Depot, Inc. (the “Company”), departed from the Company.
on June 20, 2025, the Board appointed William M. Greenman, the Company’s President and Chief Executive Officer and a member of the class of directors whose terms of office expire at the Company’s 2026 annual meeting of stockholders, to serve as chair of the Board
On June 16, 2025, Daniel N. Swisher, Jr., chair of the board of directors (the “Board”) of Cerus Corporation (the “Company”), notified the Company of his intent to retire from the Board and all committees thereof on which he served, effective immediately.
On June 17, 2025, after the Annual Meeting, HCW Biologics Inc. accepted Gary M. Winer’s resignation from the Company’s Board of Directors, effective immediately.
On June 23, 2025, Capstone Green Energy Holdings, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Christopher J. Close to serve as a director of the Company, effective June 16, 2025.
resign as senior vice president, controller and chief accounting officer of Sempra
On June 21, 2025, the Sempra Board promoted Dyan Z. Wold, the current vice president, controller and chief accounting officer of Sempra’s subsidiary Sempra Infrastructure Partners, to the position of vice president, controller and chief accounting officer of Sempra.
be appointed as the non-executive chairman of the board of directors of SDG&E
as a director of SoCalGas
the SoCalGas Board appointed Ms. Winn to serve as a director of SoCalGas and the non-executive chairman and a member of the Compensation and Safety Committees of the SoCalGas Board.
On June 21, 2025, the Board of Directors of Sempra (the “Sempra Board”) promoted Caroline A. Winn to the position of executive vice president of Sempra overseeing Southern California Gas Company (“SoCalGas”) and San Diego Gas & Electric Company (“SDG&E”), Sempra’s California utility subsidiaries.
In connection with this promotion and these appointments, Ms. Winn will resign from her current role as the chief executive officer of SDG&E but continue to serve as a director and be appointed as the non-executive chairman of the board of directors of SDG&E
On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").
elected Allan Levine to serve on the Board, effective June 23, 2025.
the Board has appointed Mr. Jeffrey M. Ettinger as the Interim Chief Executive Officer of the Company (the 'Interim CEO') and Mr. John F. Ghingo as the President of the Company (the 'President'), in each case effective as of July 14, 2025.
James P. Snee, President and Chief Executive Officer ('CEO') of the Company will be retiring at the end of the Company's fiscal year 2025, which ends October 26, 2025.
The Board has also appointed Mr. Ghingo as a member of the Board, effective as of July 14, 2025.
the Board has appointed Mr. Jeffrey M. Ettinger as the Interim Chief Executive Officer of the Company (the 'Interim CEO') and Mr. John F. Ghingo as the President of the Company (the 'President'), in each case effective as of July 14, 2025.
James P. Snee, President and Chief Executive Officer ('CEO') of the Company will be retiring at the end of the Company's fiscal year 2025, which ends October 26, 2025.
Cyndi Sirard, MD will be terminated without cause from her position as the Company’s Chief Medical Officer, effective on or about July 31, 2025
Augustine Lawlor will be terminated without cause from his position as the Company’s Chief Operating Officer, effective June 30, 2025
Mark O. Decker, Jr, age 49, was appointed Chief Executive Officer and President of the Company, effective as of June 23, 2025.
Mr. Busch was removed from his position as Chief Executive Officer and President of the Company, effective June 23, 2025. Mr. Busch will continue to serve on the board of directors of the Company (the “Board”) as non-executive Chairman.
the Board also increased the size of the Board from seven directors to eight directors and appointed Mr. Decker as a director effective June 23, 2025
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
the employment of each of Ralph D’Amico, the Company’s Chief Financial Officer and Executive Vice President and Chad L. Stephens, the Company’s President and Chief Executive Officer was terminated at the effective time of the Merger.
Daniel Herz appointed as Chief Executive Officer of the Company, Jeff Smith appointed as President of the Company, and Jeffrey Slotterback appointed as Chief Financial Officer and Secretary of the Company.
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
Daniel Herz appointed as Chief Executive Officer of the Company, Jeff Smith appointed as President of the Company, and Jeffrey Slotterback appointed as Chief Financial Officer and Secretary of the Company.
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
Jeffrey Slotterback was appointed as the sole member of the Board of Directors of the Company.
each of Mark T. Behrman, Glen A. Brown, Lee M. Canaan, Steven L. Packebush, John H. Pinkerton, and Chad L. Stephens resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the Company, effective at the effective time of the Merger on June 23, 2025.
Daniel Herz appointed as Chief Executive Officer of the Company, Jeff Smith appointed as President of the Company, and Jeffrey Slotterback appointed as Chief Financial Officer and Secretary of the Company.
the employment of each of Ralph D’Amico, the Company’s Chief Financial Officer and Executive Vice President and Chad L. Stephens, the Company’s President and Chief Executive Officer was terminated at the effective time of the Merger.
Jürg Oleas Director
Jan Philipp Jenisch Chief Executive Officer and Chairman
Maria Cristina A. Wilbur Director
Jaime Hill* President, Building Materials
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.